@article{MTMT:36892584,
	title = {Diagnostic performance of two commercially available, PPG-based smartphone applications to detect atrial fibrillation},
	url = {https://m2.mtmt.hu/api/publication/36892584},
	author = {Szőnyi, Mihály Dániel and Gausz, Flóra Diána and Bocz, Botond and Pilecky, Dávid and Muk, Balázs and Bánfi-Bacsárdi, Fanni and Földesi, Csaba László and Andréka, Péter and Szili-Török, Tamás and Kupó, Péter and Vámos, Máté},
	doi = {10.1093/ehjdh/ztag009},
	journal-iso = {EUR HEART J-DIGITAL HEALTH},
	journal = {EUROPEAN HEART JOURNAL-DIGITAL HEALTH},
	volume = {7},
	unique-id = {36892584},
	year = {2026},
	eissn = {2634-3916},
	orcid-numbers = {Szőnyi, Mihály Dániel/0009-0001-1003-4066; Gausz, Flóra Diána/0000-0002-4058-7710; Bocz, Botond/0009-0000-7716-1281; Pilecky, Dávid/0000-0001-7232-9698; Muk, Balázs/0000-0003-0821-484X; Bánfi-Bacsárdi, Fanni/0000-0002-5024-2820; Földesi, Csaba László/0000-0002-5033-117X; Andréka, Péter/0000-0003-1487-8992; Szili-Török, Tamás/0000-0002-7165-8243; Kupó, Péter/0000-0002-9422-4245; Vámos, Máté/0000-0003-1611-4443}
}

@article{MTMT:36994449,
	title = {Diagnostic challenges of Takotsubo syndrome in the context of hypertrophic obstructive cardiomyopathy phenocopy},
	url = {https://m2.mtmt.hu/api/publication/36994449},
	author = {Bánfi-Bacsárdi, Fanni and Forrai, Zsolt and Piróth, Zsolt and Muk, Balázs},
	doi = {10.1136/bcr-2025-270318},
	journal-iso = {BMJ CASE REP},
	journal = {BMJ CASE REPORTS},
	volume = {19},
	unique-id = {36994449},
	abstract = {The diagnosis of Takotsubo syndrome may be challenging in daily clinical practice. Our patient presented with an initial diagnosis of acute anterolateral ST elevation myocardial infarction, while coronary angiography showed non-obstructive coronary arteries. Transthoracic echocardiography raised the suspicion of hypertrophic obstructive cardiomyopathy (HOCM) and Takotsubo syndrome. In such clinical presentations, cardiac MRI (cMRI) plays a crucial role in differential diagnosis as part of a multimodality imaging approach. For our patient, serial cMRI studies helped to establish the diagnosis of Takotsubo syndrome during the index presentation and confirmed it retrospectively; the presence of transient hypertrophic cardiomyopathy phenocopy and left ventricular outflow tract obstruction (LVOTO) was partially due to transient oedema in the active phase of the condition. In addition, cMRI proved to be a key modality for excluding HOCM as a potential alternative cause of the dynamic LVOTO. With the implementation of complex guideline-directed medical therapy, the patient improved to the heart failure with improved ejection fraction category with a remarkable improvement in clinical status.},
	keywords = {Magnetic Resonance Imaging; heart failure},
	year = {2026},
	eissn = {1757-790X},
	orcid-numbers = {Muk, Balázs/0000-0003-0821-484X}
}

@article{MTMT:36998643,
	title = {Az albuminuria vizsgálata a csökkent ejekciós frakciójú szívelégtelenség első vonalbeli gyógyszeres terápiájának tükrében},
	url = {https://m2.mtmt.hu/api/publication/36998643},
	author = {Forrai, Zsolt and Schäffer, Pál Péter and Gergely, Tamás G and Kazay, Ádám and Hanuska, Laura Fanni and Czurkó, Kata and Pilecky, Dávid and Andréka, Péter and Piróth, Zsolt and Bánfi-Bacsárdi, Fanni and Muk, Balázs},
	doi = {10.1556/650.2026.33492},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {167},
	unique-id = {36998643},
	issn = {0030-6002},
	abstract = {Bevezetés: A vizelet albumin-kreatinin arány alapvető fontosságú a kardio-reno-metabolicus szindrómában, továbbá értékének emelkedése szívelégtelenségben kedvezőtlenebb prognózissal bír. Célkitűzés: A vizelet albumin-kreatinin arány mérése szerepének értékelése egy konszekutív, csökkent ejekciós frakciójú szívelégtelenség (HFrEF) okán hospitalizált kohorszban a modern prognózismódosító gyógyszeres terápia alkalmazhatósága és az összhalálozás vonatkozásában. Módszer: 2023. 09. 01. és 2024. 09. 01. között HFrEF miatti hospitalizáció során vizelet albumin-kreatinin arány meghatározáson átesett 168 beteg adatainak elemzését végeztük retrospektíven (felvételi paraméterek: férfi: 75%, életkor: 60 [51–70] év, diabetes: 36%, NT-proBNP: 5982 [2624–10567] pg/ml, eGFR: 59 [47–75] ml/perc/1,73 m 2 , RASi: 63%, βB: 63%, MRA: 44%, SGLT2i: 18%, négyes terápia [RASi + βB + MRA + SGLT2i]: 15%). A vizelet albumin-kreatinin arány értékei alapján a betegeket 3 csoportba soroltuk – A1: <3 mg/mmol, A2: 3–30 mg/mmol, A3: >30 mg/mmol –, és közöttük összehasonlítottuk elbocsátáskor a gyógyszeres terápia alkalmazási arányát. Vizsgáltuk az összhalálozást és annak prediktorait. Eredmények: A vizelet albumin-kreatinin arány kategóriáinak megoszlása a következőképpen alakult: 53%, 38% és 9% (A1, A2, A3). Az A2/A3 albuminuriával rendelkezők körében kisebb volt a de novo HFrEF aránya, s nagyobb arányúnak bizonyult a komorbiditások előfordulása és az NT-proBNP szintje. A súlyosabb albuminuria a prognózismódosító gyógyszeres terápia ritkább alkalmazásával függött össze (RASi: 98% vs. 94% vs. 59%, βB: 95% vs. 89% vs. 71%, MRA: 100% vs. 94% vs. 59%, SGLT2i: 84% vs. 68% vs. 41%, négyes terápia: 80% vs. 61% vs. 41%). A súlyosabb albuminuriával rendelkezők összhalálozása kedvezőtlenebb volt (7% vs. 20% vs. 29%, p = 0,026). Az egyváltozós Cox-regressziós modellben a vizelet albumin-kreatinin arány prognosztikai hatással bírt, a többváltozós elemzésben az életkor, a systolés vérnyomás és a hármas terápia (RASi + βB + MRA)/négyes terápia alkalmazása bizonyult független prediktornak. Következtetés: Eredményeink rávilágítanak a vizelet albumin-kreatinin arány mérésének jelentőségére HFrEF-ben a klinikai gyakorlatban. A prognózismódosító gyógyszeres terápia alkalmazása a nagyobb kockázatú, súlyos albuminuriával rendelkezők jelentős hányadánál kivitelezhető volt, ami alátámasztja a gyógyszeres terápia optimalizálására irányuló folyamatos erőfeszítéseket az albuminuria teljes spektrumán. Orv Hetil. 2026; 167(10): 383–395. | Introduction: Urine albumin-to-creatinine ratio (UACR) has strategic importance in cardio-kidney-metabolic syn-
		drome and leads to worse prognosis in heart failure.
		Objective: To assess the role of UACR measurement in a consecutive, hospitalized patient cohort with heart failure
		with reduced ejection fraction (HFrEF) and to analyze the effect on guideline-directed medical therapy implementa-
		tion and all-cause mortality. Methods: The data of 186 patients, hospitalized for HFrEF between 01. 09. 2023 and 01. 09. 2024, were analyzed
		retrospectively, who had UACR measured in-hospital (admission parameters: male: 75%, age: 60 [51–70] years, dia-
		betes: 36%, NT-proBNP: 5982 [2624–10567] pg/mL, eGFR: 59 [47–75] mL/min/1.73 m2, RASi: 63%, βB: 63%,
		MRA: 44%, SGLT2i: 18%, quadruple therapy [RASi + βB + MRA + SGLT2i]: 15%). Based on UACR values,
		3 groups were created – A1: <3 mg/mmol, A2: 3–30 mg/mmol, A3: >30 mg/mmol – and pharmacotherapy at
		discharge was compared among them. All-cause mortality and its predictors were investigated.
		Results: The distribution of UACR categories were: 53%, 38%, and 9% (A1, A2, A3). Patients with A2/A3 albumi-
		nuria were characterized by lower ratio of de novo HFrEF, higher comorbidity burden and NT-proBNP. Advanced
		albuminuria was associated with a lower application ratio of HFrEF pharmacotherapy (RASi: 98% vs. 94% vs. 59%, βB:
		95% vs. 89% vs. 71%, MRA: 100% vs. 94% vs. 59%, SGLT2i: 84% vs. 68% vs. 41%, quadruple therapy: 80% vs. 61% vs.
		41%). All-cause mortality rates of patients with higher albuminuria were worse (7% vs. 20% vs. 29%, p = 0.026). How-
		ever, in the univariate analysis, UACR had a prognostic effect, while in the multivariate model, age, systolic blood
		pressure and the use of triple therapy (RASi + βB + MRA)/quadruple therapy remained the independent predictors
		of all-cause mortality.
		Conclusions: Our results highlight the importance of UACR in the identification of high-risk HFrEF patients. Guide-
		line-directed medical therapy implementation was possible among them as well, underscoring the need of continuous
		therapy-optimization in wide spectrum of albuminuria.},
	year = {2026},
	eissn = {1788-6120},
	pages = {383-395},
	orcid-numbers = {Pilecky, Dávid/0000-0001-7232-9698; Andréka, Péter/0000-0003-1487-8992; Muk, Balázs/0000-0003-0821-484X}
}

@article{MTMT:37049829,
	title = {Revisiting the obesity paradox in patients with heart failure with reduced ejection fraction in the light of contemporary guideline-directed medical therapy},
	url = {https://m2.mtmt.hu/api/publication/37049829},
	author = {Gergely, Tamás G and Forrai, Zsolt and Kazay, Ádám and Schäffer, Pál Péter and Vámos, Máté and Pilecky, Dávid and Füzesi, Tamás Péter and Hanuska, Laura Fanni and Nyolczas, Noémi and Dékány, Miklós and Andréka, Péter and Piróth, Zsolt and Bánfi-Bacsárdi, Fanni and Muk, Balázs},
	doi = {10.1007/s00392-026-02865-y},
	journal-iso = {CLIN RES CARDIOL},
	journal = {CLINICAL RESEARCH IN CARDIOLOGY},
	unique-id = {37049829},
	issn = {1861-0684},
	year = {2026},
	eissn = {1861-0692},
	orcid-numbers = {Gergely, Tamás G/0000-0003-1972-2065; Vámos, Máté/0000-0003-1611-4443; Pilecky, Dávid/0000-0001-7232-9698; Nyolczas, Noémi/0000-0001-9466-0939; Andréka, Péter/0000-0003-1487-8992; Muk, Balázs/0000-0003-0821-484X}
}

@article{MTMT:35653099,
	title = {Eligibility for rapid up-titration of guideline-directed medical therapy of real-world patients hospitalised for heart failure},
	url = {https://m2.mtmt.hu/api/publication/35653099},
	author = {Bánfi-Bacsárdi, Fanni and Forrai, Zsolt and Kazay, Ádám and Füzesi, Tamás and Vámos, Máté and Gergely, Tamás G and Pilecky, Dávid and Komáromi, Anna and Szőnyi, Mihály Dániel and Papp, Emese and Solymossi, Balázs and Baksa, Veronika and Andréka, Péter and Piróth, Zsolt and Nyolczas, Noémi and Muk, Balázs},
	doi = {10.1159/000543070},
	journal-iso = {CARDIOLOGY},
	journal = {CARDIOLOGY},
	volume = {150},
	unique-id = {35653099},
	issn = {0008-6312},
	abstract = {Introduction and aims: The 2023 Focused Update of the 2021 ESC Heart Failure (HF) Guidelines recommends the rapid up-titration (RT) of guideline-directed medical therapy (GDMT) for all patients hospitalised for HF to improve prognosis in light of STRONG-HF trial. However, the real-world feasibility of RT and the optimal selection of suitable patients may cause difficulties, as the STRONG-HF trial applied strict randomisation criteria. We aimed to assess the proportion of hospitalised HF patients suitable for RT after discharge.Methods: The proportion of patients eligible for RT based on the basic in- and exclusion criteria of the STRONG-HF trial (systolic blood pressure [SBP]≥100mmHg, heart rate [HR]≥60min-1, serum potassium≤5mmol/L, eGFR≥30mL/min/1.73m2, discharge NT-proBNP>1500pg/mL) was assessed in a consecutive patient cohort at a tertiary referral center between 01/04/2021 and 31/12/2023. Results: Data from 408 consecutive patients were analysed (male: 71%; age: 62[51-72]years; left ventricular ejection fraction: 27[20-35]%; HFrEF: 82%; hypertension: 67%; diabetes: 36%; atrial fibrillation: 47%). 78% of the patients were suitable for RT based on the SBP criterion, 93% on HR, 89% on serum potassium, and 91% on eGFR values. Thus, 60% were eligible for RT using the combined assessment of these parameters. When including the NT-proBNP value as well (60%), 34% of the cohort were eligible for RT.Conclusions: Based on our study, the proportion of patients suitable for RT of GDMT ranged from 34% to 60% based on the basic eligibility indicators of the STRONG-HF trial. Our results highlight the strategic importance of careful selection of patients eligible for RT.},
	year = {2025},
	eissn = {1421-9751},
	pages = {500-510},
	orcid-numbers = {Vámos, Máté/0000-0003-1611-4443; Pilecky, Dávid/0000-0001-7232-9698; Solymossi, Balázs/0000-0002-8652-706X; Andréka, Péter/0000-0003-1487-8992; Nyolczas, Noémi/0000-0001-9466-0939; Muk, Balázs/0000-0003-0821-484X}
}

@article{MTMT:35658607,
	title = {Therapeutic Consequences and Prognostic Impact of Multimorbidity in Heart Failure: Time to Act},
	url = {https://m2.mtmt.hu/api/publication/35658607},
	author = {Bánfi-Bacsárdi, Fanni and Kazay, Ádám and Gergely, Tamás G and Forrai, Zsolt and Füzesi, Tamás Péter and Hanuska, Laura Fanni and Schäffer, Pál Péter and Pilecky, Dávid and Vámos, Máté and Vértes, Vivien and Dékány, Miklós and Andréka, Péter and Piróth, Zsolt and Nyolczas, Noémi and Muk, Balázs},
	doi = {10.3390/jcm14010139},
	journal-iso = {J CLIN MED},
	journal = {JOURNAL OF CLINICAL MEDICINE},
	volume = {14},
	unique-id = {35658607},
	abstract = {Background/Objectives: In heart failure (HF) with reduced ejection fraction (HFrEF), the early diagnosis and proper treatment of comorbidities (CMs) are of fundamental relevance. Our aim was to assess the prevalence of CMs among real-world patients requiring hospitalisation for HFrEF and to investigate the effect of CMs on the implementation of guideline-directed medical therapy (GDMT) and on all-cause mortality (ACM). Methods: The data of a consecutive HFrEF patient cohort hospitalised for HF between 2021 and 2024 were analysed retrospectively. Sixteen CMs (6 CV and 10 non-CV) were considered. Patients were divided into three categories: 0–3 vs. 4–6 vs. ≥7 CMs. GDMT at discharge and ACM were compared among CM categories. The predictors of 1-year ACM were also evaluated. Results: From the 388 patients (male: 76%, age: 61 [50–70] years; NT-proBNP: 5286 [2570–9923] pg/mL; ≥2 cardiovascular–kidney–metabolic disease overlap: 46%), a large proportion received GDMT (RASi: 91%; βB: 85%; MRA: 95%; SGLT2i: 59%; triple therapy [TT: RASi+βB+MRA]: 82%; quadruple therapy [QT: TT + SGLT2i]: 54%) at discharge. Multimorbidity was accompanied with a (p < 0.05) lower application ratio of RASi (96% vs. 92% vs. 85%; 0–3 vs. 4–6 vs. ≥7 CMs) and βB therapy (94% vs. 85% vs. 78%), while MRA (99% vs. 94% vs. 94%) and SGTL2i use (61% vs. 59% vs. 57%) did not differ (p > 0.05). Patients with multimorbidity were less likely to be treated with TT (93% vs. 82% vs. 73%, p = 0.001), while no difference was detected in the implementation of QT (56% vs. 54% vs. 50%, p = 0.685). The 1-year ACM of patients with an increased burden of CMs was higher (9% vs. 13% vs. 25%, p = 0.003). The risk of 1-year ACM was favourably affected by the use of TT/QT and less severe left ventricular systolic dysfunction, while having ≥5 CMs had an unfavourable impact on prognosis. Conclusions: According to our real-world analysis, HFrEF patients with an increased burden of CMs can expect a less favourable outcome. However, modern GDMT can even be applied in this patient population, resulting in a significantly improved prognosis. Thus, clinicians should insist on the early, conscious implementation of a prognosis-modifying drug regime in multimorbid HF patients as well.},
	year = {2025},
	eissn = {2077-0383},
	orcid-numbers = {Pilecky, Dávid/0000-0001-7232-9698; Vámos, Máté/0000-0003-1611-4443; Andréka, Péter/0000-0003-1487-8992; Nyolczas, Noémi/0000-0001-9466-0939; Muk, Balázs/0000-0003-0821-484X}
}

@article{MTMT:36068942,
	title = {Differences in the application of guideline-directed medical therapy among patients with de novo and previously confirmed diagnosis of heart failure with reduced ejection fraction: real-world experience of two tertiary cardiac centers},
	url = {https://m2.mtmt.hu/api/publication/36068942},
	author = {Bánfi-Bacsárdi, Fanni and Gergely, Tamás G and Forrai, Zsolt and Kazay, Ádám and Füzesi, Tamás and Pilecky, Dávid and Vámos, Máté and Hanuska, Laura and Schäffer, Pál Péter and Majoros, Zsuzsanna and Török, Gábor Márton and Borsányi, Tünde and Duray, Gábor Zoltán and Kiss, Róbert Gábor and Andréka, Péter and Piróth, Zsolt and Nyolczas, Noémi and Muk, Balázs},
	doi = {10.1016/S0735-1097(25)02094-7},
	journal-iso = {J AM COLL CARDIOL},
	journal = {JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY},
	volume = {85},
	unique-id = {36068942},
	issn = {0735-1097},
	year = {2025},
	eissn = {1558-3597},
	pages = {1610-1610},
	orcid-numbers = {Pilecky, Dávid/0000-0001-7232-9698; Vámos, Máté/0000-0003-1611-4443; Duray, Gábor Zoltán/0000-0003-1286-6576; Kiss, Róbert Gábor/0000-0003-0514-7530; Andréka, Péter/0000-0003-1487-8992; Nyolczas, Noémi/0000-0001-9466-0939; Muk, Balázs/0000-0003-0821-484X}
}

@article{MTMT:36082734,
	title = {Sacubitril/Valsartan Improves Hemodynamic Parameters of Pulmonary and Systemic Circulation in Patients Awaiting Heart Transplantation},
	url = {https://m2.mtmt.hu/api/publication/36082734},
	author = {Ráduly, Arnold Péter and Saman Kothalawala, Edward and Balogh, László and Majoros, Zsuzsanna and Pólik, Zsófia and Fülöp, László and Győry, Ferenc and Nagy, László and Bódi, Beáta and Kovács, Máté Balázs and Csanádi, Zoltán and Papp, Zoltán and Muk, Balázs and Borbély, Attila},
	doi = {10.3390/jcm14082539},
	journal-iso = {J CLIN MED},
	journal = {JOURNAL OF CLINICAL MEDICINE},
	volume = {14},
	unique-id = {36082734},
	abstract = {Background/Objectives: Heart transplantation (HTX) is the definitive treatment for advanced heart failure (AdHF). The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (S/V) has been shown to reduce heart failure (HF) hospitalizations and mortality when compared to conventionally administered HF medications (i.e. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs)). Nevertheless, limited data are available on the hemodynamic (HD) effects of ARNI in patients with AdHF. Therefore, the aim of the present study was to compare echocardiographic, laboratory, and HD parameters relevant to HF before and after switching to ARNI in patients with AdHF awaiting HTX. Methods: A retrospective analysis was conducted utilizing available data on HD parameters, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, data on kidney function, HF therapy, and comorbidities. The study cohort comprised 13 AdHF patients (3 women, 10 men; mean age 56.4 ± 9 years) of whom 53.8% presented with non-ischemic and 46.2% with ischemic etiology. All patients were awaiting heart transplantation (HTX) and were transitioned to ARNI therapy between 2018 and 2021. Results: After switching to ARNI, we observed significant improvements: in left ventricular ejection fraction (LVEF: 27.27 ± 1.04% vs. 23.65 ± 1.02%, p = 0.03; data are given as mean ± SEM after vs. before ARNI therapy, respectively), cardiac output (CO: 4.90 ± 0.35 L/min vs. 3.83 ± 0.24 L/min, p = 0.013), and stroke volume (SV: 70.9 ± 5.9 mL vs. 55.5 ± 4.12 mL, p = 0.013). Significant reductions in systemic vascular resistance (SVR: 1188 ± 79.8 vs. 1600 ± 100 DS/cm5, p = 0.004) and pulmonary vascular resistance (PVR: 232.5 ± 34.8 vs. 278.9 ± 31.7 DS/cm5, p = 0.04) were also noted. Central venous pressure (CVP), pulmonary arterial systolic and diastolic pressures (PAPs and PAPd), pulmonary capillary wedge pressure (PCWP), and NT-proBNP levels did not exhibit significant changes upon ARNI administration. Conclusions: Early transition to ARNI therapy offers significant benefits for invasively measured hemodynamic parameters in patients with AdHF, potentially aiding in the stabilization and improvement of this vulnerable patient population.},
	year = {2025},
	eissn = {2077-0383},
	orcid-numbers = {Ráduly, Arnold Péter/0000-0003-0616-8405; Muk, Balázs/0000-0003-0821-484X}
}

@article{MTMT:36165611,
	title = {A csökkent ejekciós frakciójú szívelégtelenség kezelése: fókuszban az első vonalbeli gyógyszeres terápia},
	url = {https://m2.mtmt.hu/api/publication/36165611},
	author = {Muk, Balázs and Bánfi-Bacsárdi, Fanni},
	journal-iso = {ORVOSTOVÁBBKÉPZŐ SZLE},
	journal = {ORVOSTOVÁBBKÉPZŐ SZEMLE},
	volume = {32},
	unique-id = {36165611},
	issn = {1218-2583},
	abstract = {Összefoglalónkban a krónikus csökkent ejekciós frakciójú szívelégtelenség (HFrEF) modern, első vonalbeli gyógyszeres kezelésének átalakulásáról, négyes „pillérterápiájáról”, a gyorsított terápiaoptimalizációról számolunk be az Európai Kardiológiai Társaság 2021-es és 2023-as, megújított szívelégtelenség-irányelvének tükrében, emellett áttekintjük a nem farmakológiai kezelési lehetőségeket is.},
	year = {2025},
	pages = {11-16},
	orcid-numbers = {Muk, Balázs/0000-0003-0821-484X}
}

@article{MTMT:36174452,
	title = {The Feasibility of a Guideline-Directed Medical Therapy Rapid Up-Titration Programme Among Real-World Heart Failure Patients: A Multicentre Observational Study.},
	url = {https://m2.mtmt.hu/api/publication/36174452},
	author = {Bánfi-Bacsárdi, Fanni and Ráduly, Arnold and Borbély, Attila and Nyolczas, Noémi and Szilagyi, Attila and Gergely, Tamás G and Forrai, Zsolt and Papp, Judit and Ratosi, Orsolya and Racz, Tunde and Hati, Krisztina and Kocsis, Ildiko and Csanádi, Zoltán and Duray, Gábor Zoltán and Andréka, Péter and Piróth, Zsolt and Muk, Balázs},
	doi = {10.3390/jcm14103611},
	journal-iso = {J CLIN MED},
	journal = {JOURNAL OF CLINICAL MEDICINE},
	volume = {14},
	unique-id = {36174452},
	abstract = {Background: The 2023 ESC Heart Failure (HF) Guidelines recommend the rapid up-titration of guideline-directed medical therapy (GDMT) for all patients after HF hospitalisation. Real-world data on the implementation of a rapid up-titration programme (RTP) are scarce. Methods: We aimed to summarise the primary experiences of a six-week RTP in a multicentre observational study of five cardiology centres, evaluating the GDMT applied and the target doses (TDs) achieved during the RTP. The safety of RTP in relation to exceeding the "safety indicators" used in the STRONG-HF trial and any serious adverse events were observed. Changes in the left ventricular ejection fraction (LVEF) after RTP were evaluated. Results: Among the 90 consecutive patients (age: 56 [49-63] years, HFrEF: 96%, NT-proBNP at discharge: 1390 [735-2835] pg/mL; continuous variables are presented as median and interquartile ranges, while categorical variables are shown as absolute numbers and percentages, respectively), a remarkable proportion of patients received GDMT at hospital discharge; however, target doses were rarely achieved (RASi: 100%, TD RASi: 11%; betaB: 97%, TD betaB: 6%; MRA: 99%, TD MRA: 82%; SGLT2i: 98%, TD SGLT2i: 98%; triple therapy [TT: RASi + betaB + MRA]: 96%, TD TT: 2%, quadruple therapy [QT: RASi + betaB + MRA]: 94%, TD QT: 2%). After the six-week RTP, 100% of the total cohort (TC) were receiving RASi; 99-99-99% were receiving betaB, MRA, and SGLT2i medications; and altogether, 98-98% were on TT and QT. In total, 78-78% of the patients received ≥50% of the TDs of TT and QT, while 51-51% of the TC were on TDs of TT and QT. During the RTP, no serious adverse events were observed. Between two and four months after the RTP, 51% of HFrEF patients evolved to the HFimpEF category. Conclusions: The present multicentre, observational study confirms that RTP is feasible and safe in real-world clinical practice, leading to a remarkably large proportion of patients receiving GDMT by the end of the six-week RTP, resulting in a significant increase in LVEF.},
	keywords = {heart failure; guideline-directed medical therapy; heart failure outpatient clinic},
	year = {2025},
	eissn = {2077-0383},
	orcid-numbers = {Nyolczas, Noémi/0000-0001-9466-0939; Duray, Gábor Zoltán/0000-0003-1286-6576; Andréka, Péter/0000-0003-1487-8992; Muk, Balázs/0000-0003-0821-484X}
}